Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study.,Annals of Clinical and Translational Neurology

当前位置： X-MOL 学术 › Ann. Clin. Transl. Neur. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study.
Annals of Clinical and Translational Neurology ( IF 4.4 ) Pub Date : 2019-11-04 , DOI: 10.1002/acn3.50932
Lara Kay _{1,

2} , Nina Merkel _{1,

2} , Anemone von Blomberg _{1,

2} , Laurent M Willems _{1,

2} , Sebastian Bauer _{1,

2} , Philipp S Reif _{1,

2} , Susanne Schubert-Bast _{1,

2,

3} , Felix Rosenow _{1,

2} , Adam Strzelczyk _{1,

2}

Affiliation

We sought to evaluate the efficacy and tolerability of intranasal midazolam (in‐MDZ) as first‐line inhospital therapy in patients with status epilepticus (SE) during continuous EEG recording.

中文翻译：